Last reviewed · How we verify

bortezomib + rituximab — Competitive Intelligence Brief

bortezomib + rituximab (bortezomib + rituximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor + monoclonal antibody combination. Area: Oncology.

phase 3 Proteasome inhibitor + monoclonal antibody combination 26S proteasome (bortezomib); CD20 (rituximab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

bortezomib + rituximab (bortezomib + rituximab) — Jonsson Comprehensive Cancer Center. Bortezomib inhibits the proteasome to trigger cancer cell death, while rituximab targets CD20 on B cells to enhance immune-mediated tumor destruction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
bortezomib + rituximab TARGET bortezomib + rituximab Jonsson Comprehensive Cancer Center phase 3 Proteasome inhibitor + monoclonal antibody combination 26S proteasome (bortezomib); CD20 (rituximab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proteasome inhibitor + monoclonal antibody combination class)

  1. Jonsson Comprehensive Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bortezomib + rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/bortezomib-rituximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: